Our primary hypothesis is that inhibition of IL-6 signalling with a single intravenous infusion of anti-IL6R mAb, tocilizumab, in individuals with psychosis and elevated IL-6 at baseline, will attenuate symptoms of anhedonia and amotivation in patients with psychosis, relative to placebo. Here, IL6 is linked to psychotic disorder.